Spots Global Cancer Trial Database for xtandi
Every month we try and update this database with for xtandi cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | NCT02960022 | Prostate Cancer | enzalutamide abiraterone ace... prednisone | 18 Years - | Astellas Pharma Inc | |
| Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients | NCT01902251 | Prostate Cancer Pharmacokinetic... | Enzalutamide ta... Enzalutamide ca... | 18 Years - | Astellas Pharma Inc | |
| Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer | NCT02918968 | Prostate Cancer | Enzalutamide Flutamide Androgen depriv... | 20 Years - | Astellas Pharma Inc | |
| Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | NCT05191017 | Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration Resi... Castration Resi... | NUV-422 Enzalutamide | 18 Years - | Nuvation Bio Inc. | |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | NCT02960022 | Prostate Cancer | enzalutamide abiraterone ace... prednisone | 18 Years - | Astellas Pharma Inc | |
| A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | NCT02124668 | Castration-Resi... Prostate Cancer | Enzalutamide | - | Astellas Pharma Inc | |
| Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer | NCT01565928 | Prostate Cancer | MDV3100 | 18 Years - | Pfizer | |
| A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden | NCT03328364 | Metastatic Cast... | enzalutamide docetaxel | 18 Years - | Astellas Pharma Inc | |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | NCT02960022 | Prostate Cancer | enzalutamide abiraterone ace... prednisone | 18 Years - | Astellas Pharma Inc | |
| Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | NCT05191017 | Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration Resi... Castration Resi... | NUV-422 Enzalutamide | 18 Years - | Nuvation Bio Inc. | |
| Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer | NCT02918968 | Prostate Cancer | Enzalutamide Flutamide Androgen depriv... | 20 Years - | Astellas Pharma Inc | |
| A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer | NCT02116582 | Metastatic Cast... | Enzalutamide | 18 Years - | Astellas Pharma Inc | |
| A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide | NCT01977651 | Metastatic Cast... | Enzalutamide | - | Astellas Pharma Inc | |
| An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants | NCT02294461 | Progressive Met... | Enzalutamide Placebo | 18 Years - | Astellas Pharma Inc | |
| A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone | NCT02288247 | Metastatic Cast... | Enzalutamide Docetaxel Prednisolone Placebo | 18 Years - | Astellas Pharma Inc | |
| An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | NCT04076059 | Metastatic Horm... | Enzalutamide Placebo Androgen depriv... | 18 Years - | Astellas Pharma Inc | |
| Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer | NCT02918968 | Prostate Cancer | Enzalutamide Flutamide Androgen depriv... | 20 Years - | Astellas Pharma Inc | |
| Long-Term Specified Drug Use-Results Survey for Xtandi Capsule | NCT02669771 | Castration-resi... | enzalutamide | - | Astellas Pharma Inc | |
| A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy | NCT03641560 | Metastatic Cast... | Enzalutamide Androgen depriv... | 18 Years - | Astellas Pharma Inc | |
| European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) | NCT02495974 | Metastatic Cast... | enzalutamide | - | Astellas Pharma Inc | |
| A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden | NCT03328364 | Metastatic Cast... | enzalutamide docetaxel | 18 Years - | Astellas Pharma Inc | |
| Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases. | NCT03869762 | Castration-resi... Metastatic Canc... Bone Metastases | Xgeva Xtandi | 18 Years - | Cancer Trials Ireland | |
| Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates | NCT01911728 | Pharmacokinetic... Castration Resi... | MDV3100 Pioglitazone Warfarin Omeprazole Midazolam | 18 Years - | Astellas Pharma Inc | |
| An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants | NCT02294461 | Progressive Met... | Enzalutamide Placebo | 18 Years - | Astellas Pharma Inc | |
| Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study | NCT03325127 | Prostatic Neopl... | radium Ra 223 d... Zytiga Xtandi | 40 Years - | Bayer | |
| Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer | NCT01565928 | Prostate Cancer | MDV3100 | 18 Years - | Pfizer | |
| A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma | NCT02528643 | Advanced Hepato... | Enzalutamide Placebo | 18 Years - | Astellas Pharma Inc | |
| An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | NCT04076059 | Metastatic Horm... | Enzalutamide Placebo Androgen depriv... | 18 Years - | Astellas Pharma Inc | |
| Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone | NCT02640534 | Cancer of the P... Prostate Cancer | Enzalutamide Metformin | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study | NCT03325127 | Prostatic Neopl... | radium Ra 223 d... Zytiga Xtandi | 40 Years - | Bayer | |
| Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide | NCT01946165 | Prostate Cancer | Abiraterone Ace... Prednisone Enzalutamide LHRHa | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment | NCT02441517 | Metastatic Cast... | Enzalutamide | 18 Years - | Astellas Pharma Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
